Ph+ Acute Lymphoblastic Leukemia Not Yet Recruiting Phase 4 Trials for Dasatinib (DB01254)

IndicationStatusPhase
DBCOND0080011 (Ph+ Acute Lymphoblastic Leukemia)Not Yet Recruiting4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02690922Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia PatientsTreatment